I. Critical Audit — PI 3.3 → PI 3.4 Delta Log
Documenting structural adjustments, equations updates, and logic corrections.
PhytoIntelligence version 3.4 represents a formal, complete operational overhaul. By targeting and eliminating nine critical faults identified in the v3.3 specification, this update solidifies the mathematical foundations of the pipeline, providing stable boundary conditions for the underlying deconvolution engine.
| Ref | PI 3.3 Architectural Fault | Severity | PI 3.4 Fix Applied |
|---|---|---|---|
| F-01 |
CES Denominator Instability
The ln(Risk × Cost) factor becomes undefined/negative when product is ≤ 1, reversing scoring direction.
|
CRITICAL | Introduced bounded Risk Penalty Factor ρ = 1 + ln(1 + R × TCI). Always guarantees ≥ 1, preventing denominator singularity. |
| F-02 | Pharmacokinetic Overlap "Bioavailability" and "ADME" parameters double-counted compound absorption. | HIGH | Separated metabolic metrics explicitly into Oral Bioavailability Coefficient (OBC) and Metabolic Stability Index (MSI). |
| F-03 | Ambiguous Cost Metric "Cost" variable had no unit derivation, introducing non-pharmacological biases. | HIGH | Eliminated raw financial tracking. Replaced with Translational Cost Index (TCI), acting as a log-scaled proxy for dosage and burden. |
| F-04 | Incorrect Bliss Formula Implementation Bliss independence model shown for N=2, while a 6-node stack represents 15 distinct pairs. | HIGH | Created an exhaustive 6 × 6 Synergy Matrix; aggregate performance determined via 15-pair product chain. |
| F-05 | Undefined DSV Parameter The 6-Dimensional Diagnostic State Vector (DSV) was referenced but lacked specifications. | HIGH | Fully defined the DSV across 6 biological, orthogonal vectors with clear, numeric scoring rules (Section IV). |
| F-06 | Unresolved PK Synchronization No time-alignment constraint for different Tmax nodes when integrated inside a single capsule. | MEDIUM | Introduced the Pharmacokinetic Alignment Score (PKAS) algorithm with strict delta limits (≤ 2h). |
| F-07 | Ambiguous Gating Criteria Logic validation lacked strict replication, power, or statistical significance definitions. | MEDIUM | Enforced strict, hard logic gates: minimum 2 independent replications, active size n ≥ 30 (or in vivo), and d ≥ 0.30 effect size. |
| F-08 | Arbitrary Node Mass Distribution 250–300 mg active ranges defined without linkage to relative efficacy coefficients. | MEDIUM | Developed the CES-Weighted Mass Allocation (CWMA) formula. Individual node volume scales dynamically by normalized ranking. |
| F-09 | CYP3A4 Safety Vulnerability No mechanism to screen kinetic adjuvants (Node 6) for drug-drug interactions. | HIGH | Introduced the Safety Interaction Index (SII) gate (Step 10a). Protects pathways against P-gp/CYP clinical interactions. |
II. Operational Protocol — The 12-Step Sequence
Expanded execution path requiring mandatory sequential checkpoint validation.
Each candidate formulation must systematically clear all twelve checkpoints in serial order. Bypassing any step instantly invalidates the resulting molecular stack's pedigree.
| Step | Validation Step Name | Procedural Description | Hard Gate Parameter |
|---|---|---|---|
| 01 | Anomaly Observation | Identify pathology or target diagnosis. Establish clear therapeutic endpoint goals (e.g., cell regulation) and record comorbidities. | Pre-Execution Trace |
| 02 | Intel Requirement | Isolate relevant molecular pathways, target receptors, and enzymes. Map all components strictly to PubMed / Scopus publications. | MiniPASS ≥ 3 citations |
| 02a ★ | Confidence Tier Pre-Screen | Apply rigorous quality tiering (T1–T4) based on published dataset architecture. Filter out clinical models resting on unstable data. | T4-Only → Excluded |
| 03 | Pathological Hypothesis | Deconstruct clinical drivers into the 6-Dimensional Diagnostic State Vector (DSV). Map primary/secondary targets to specific metrics. | Dimension Mapping |
| 04 | Experimental Design | Apply physical 750 mg volumetric ceiling. Formulate provisional nodes (Primary, Secondary, Synergy, Epigenetic, Kinetic, Adjuvant). | Pre-allocation Target |
| 05 | Collection | Compile quantitative metrics (IC50, Tmax, t½, Cmax, OBC, MSI) from literature. Strictly reject molecular shape structural inference models. | LHFP Gate (No Inferences) |
| 06 | DSV Analysis | Score candidate compounds across 6 biological channels (D1–D6). Rank choices according to final calculated DSV density. | Score-Rank Decoupling |
| 07 | Logic-Gating | Systematically discard nodes failing hard replicability indices, insufficient sample sizing, or negligible effect bounds. | 2+ Reps, n≥30, d≥0.30 |
| 08 | Node Selection | Select final 6 node compounds. Deploy the CWMA algorithm to compute dynamic mass distribution. Reserve ≥10 mg capsule space. | CWMA Verification |
| 09 | Synergy Simulation | Calculate full 6 × 6 matrix elements. Solve aggregate Network Synergy Index (NSI). Identify and remove antagonistic couples. | NSI ≥ 0.90 (Pairs ≥ 0.8) |
| 10 | PK Alignment | Compute alignments relative to primary index node. Direct discordant values into advanced delayed-release formulation tracks. | PKAS Gate (|ΔTmax| ≤ 2h) |
| 10a ★ | Safety Interaction Gate | Run multi-node compound screening against critical metabolic systems (CYP3A4, P-gp). Mitigate drug interaction profiles. | SII ≤ 0.25 Gate |
| 11 | Conclusion & Formulation | Lock the 6+1 physical structure. Document final dosing allocations, kinetic indices, and therapeutic thresholds into the summary files. | Locked Blueprint |
| 12 | Reporting | Synthesize comprehensive LaTeX reports, physical recipes, and operational logs. Publish to Zenodo archive for peer scrutiny. | LHFP Provenance Audit |
III. Computational Models
Refined mathematical frameworks for safety, alignment, and network-wide synergy determination.
III-A | Compound Efficacy Score (CES) — Corrected Formula
Fixes PI 3.3 computational risks by adding a protective barrier against denominator singularity and isolating bioavailability pathways from ADME descriptors.
Where ρ(R, TCI) = 1 + ln(1 + R × TCI) is the Bounded Risk Penalty Factor
| Variable | Functional Definition | Numeric Bounds / Units |
|---|---|---|
| WM / WV | Weight coefficients allocated to raw mechanistic discovery versus clinical validation metrics. | 0.0 – 1.0 (Sum = 1.0) |
| Mechanistic Score | Quantified target-specific, peer-verified mechanism of action (MoA) pathways. | 1.0 – 10.0 |
| Validation Score | Assigned clinical weight derived from clinical phase success data and target trial efficacy. | 0.0 – 10.0 |
| Plausibility | Consensus rating measuring clinical translatability expectations. | 0.0 – 1.0 |
| ρ(R, TCI) | Risk Penalty Factor protecting denominator evaluation. Always resolves ≥ 1.0. | ≥ 1.0 |
| R | Empirical risk coefficient rating severe adverse reaction potential. | 0.0 – 1.0 |
| TCI | Translational Cost Index. Expresses log-scaled dose burden: log10(IC50human / IC50cell). | 0.0 – 3.0 |
| OBC | Oral Bioavailability Coefficient. Standard fraction of unchanged drug entering system. | 0.0 – 1.0 |
| MSI | Metabolic Stability Index. Fraction of active compound surviving initial hepatic first-pass. | 0.0 – 1.0 |
III-B | 6 × 6 Synergy Matrix — Network Synergy Index
Addresses PI 3.3 fault F-04. A complete 6-node array produces a network topology requiring C(6,2) = 15 distinct relational pathways to evaluate. Pairwise bliss limits must hold above 0.8, targeting an overall system score NSI ≥ 0.90.
E(a,b) = E(a) + E(b) - E(a)·E(b)
SI(i,j) = E(observed) / E(a,b)
NSI = (∏ SI(i,j) for all 15) ^ (1/15)
| Node Mapping | N1 Primary | N2 Secondary | N3 Synergy A | N4 Synergy B | N5 Epigenetic | N6 Kinetic |
|---|---|---|---|---|---|---|
| N1 Primary | — | SI(1,2) | SI(1,3) | SI(1,4) | SI(1,5) | SI(1,6) |
| N2 Secondary | — | — | SI(2,3) | SI(2,4) | SI(2,5) | SI(2,6) |
| N3 Synergy A | — | — | — | SI(3,4) | SI(3,5) | SI(3,6) |
| N4 Synergy B | — | — | — | — | SI(4,5) | SI(4,6) |
| N5 Epigenetic | — | — | — | — | — | SI(5,6) |
| N6 Kinetic | — | — | — | — | — | — |
All 15 SI nodes must satisfy the SI ≥ 0.8 additive boundary constraint. Network Synergy Index (geometric mean) must resolve NSI ≥ 0.90 to secure passage.
III-C | Pharmacokinetic Alignment Score (PKAS) — New in PI 3.4
Addresses PI 3.3 fault F-06. Co-administration within a single delivery capsule assumes consistent absorption windows. Compounds with significantly divergent Tmax values fail to build co-present concentration peaks, rendering baseline synergy modeling inaccurate.
Tmax_window: 4 hours default boundary window
Acceptance Bound: PKAS(i) ≥ 0.5 (Implies |ΔTmax| ≤ 2h)
Failure Correction: Enteric coating, modified-release pelletizing, or staggered dosage timing is mandatory for aberrant nodes.
III-D | Safety Interaction Index (SII) — New in PI 3.4
Addresses PI 3.3 fault F-09. Because Node 6 often relies on active CYP3A4/P-gp enzyme inhibition to bolster systemic bio-presence, a strict safety filter protects the subject profile against severe drug-drug interactions (DDI).
| SII Range | Systemic Classification | Mandatory Engineering Action Required |
|---|---|---|
| 0.00 – 0.10 | Negligible Risk | Proceed with standard pipeline compilation. Note status within final reports. |
| 0.11 – 0.25 | Low Risk | Proceed. Insert clear system contraindication warnings inside the final release notes. |
| 0.26 – 0.50 | Moderate Risk | Forced node dose titration or node substitution required to mitigate drug interaction pathways. |
| > 0.50 | High Risk | HARD SYSTEM FAIL. Node 6 must be substituted immediately. Stack pipeline terminates. |
IV. The 6-Dimensional Diagnostic State Vector (DSV)
Evaluating candidate chemistry across six orthogonal biological dimensions.
Each candidate is systematically processed across six orthogonal dimensions, yielding an analytical biological signature vector. The highest component value dictates its primary node placement.
| Dim. | Dimension Name | Biological Scope & Targets | Scoring Rubric (0–10) | Node Relevance |
|---|---|---|---|---|
| D1 | Genomic / Transcriptomic | Direct modification of gene expression, transcription factor activity, oncogene suppression (mTOR, KRAS, TP53 pathway engagement) | 0: No evidence 5: In vitro data 10: In vivo / RCT confirmation |
Node 1 (Primary Driver) |
| D2 | Metabolic Flux | Glycolysis, OXPHOS, lipid metabolism, GLUT transporter modulation, mitochondrial bioenergetics | 0: No evidence 5: Cell metabolomics 10: In vivo flux evidence |
Node 2 (Secondary Driver) |
| D3 | Redox / Antioxidant | ROS scavenging, Nrf2/HO-1 activation, GSH pathway modulation, lipid peroxidation inhibition | 0: No evidence 5: DPPH/FRAP assay 10: Nrf2 in vivo validation |
Node 3 (Synergy A) |
| D4 | Immune / Inflammatory | Cytokine modulation (IL-6, TNF-α, NF-κB), immune contexture, macrophage polarization, inflammasome activity | 0: No evidence 5: In vitro cytokine test 10: In vivo immune validation |
Node 4 (Synergy B) |
| D5 | Epigenetic | DNA methylation (DNMT inhibition), histone acetylation (HDAC inhibition), miRNA regulation, chromatin remodeling | 0: No evidence 5: HDAC IC50 reported 10: Epigenome-wide RCT evidence |
Node 5 (Epigenetic) |
| D6 | Pharmacokinetic / ADME | CYP enzyme modulation, P-gp inhibition, bioavailability enhancement, t½ extension, plasma protein binding | 0: No PK data 5: CYP IC50 in vitro 10: Human PK study validated |
Node 6 (Kinetic Adjuvant) |
Broad-Spectrum Candidate Qualification
Where a candidate scores ≥ 40 across all 6 parameters, it qualifies as a "Broad-Spectrum Candidate". Such structures are eligible to occupy secondary nodes at proportional mass offsets. When node allocation overlaps occur, the candidate carrying the superior CES score holds dominant rank.
V. Confidence Tier System — New in PI 3.4
Applying Seshat's Axiom (1=1=1 Law) to balance model confidence.
Seshat's Axiom explicitly mandates that clinical validity and empirical source confidence are tied directly to quantitative calculations. We do not evaluate high target affinity and low validation trials on equivalent conceptual paths.
| Confidence Tier | Evidence Standard Definitions | Representative Paradigm Examples | CES Multiplier | Stack Eligibility Limit |
|---|---|---|---|---|
| T1 ★★★★ | Randomized Controlled Trial (Human model, n ≥ 30 subjects, pre-registered tracking) | Phase II/III clinical trial, Cochrane meta-analysis review | 1.00 (No penalty) | Primary & Secondary Nodes (Highly Preferred) |
| T2 ★★★ | Controlled In Vivo Study (Animal disease models, ≥ 2 independent control groups) | Murine xenograft, rat high-fat diet metabolic profiles | 0.75 | All available nodes (Standard compliance) |
| T3 ★★ | In Vitro / Cell-Line Study (≥ 2 independent laboratory replicates, IC50 targets published) | MCF-7 cancer line cytotoxicity assay, HepG2 mitochondrial profile | 0.50 | Allowed for all nodes (Requires clear qualification disclosures) |
| T4 ★ | Computational Model / Molecular Docking / Single-lab Unreplicated Paper | In silico binding docking simulation, single laboratory thesis | 0.25 | Synergy & Epigenetic Nodes Only (Flagged warning marker) |
VI. Stoichiometric Architecture — 750 mg Capsule
Algorithmic mass distribution designed to optimize compound efficacy footprints.
VI-A | CES-Weighted Mass Allocation (CWMA) Algorithm
Addresses PI 3.3 fault F-08. Resolves fixed-range distribution issues by using normalized scoring vectors to distribute chemical masses dynamically inside physical volume envelopes.
r(i) = CES(i) / Σ CES(j) for j = 1..6
m(i) = r(i) × M_budget
Where M_budget = 740 mg (yielding ≥ 10 mg excipient matrix)
• Sum of allocated node masses (Σ m(i)) must strictly remain ≤ 740 mg.
• Individual active node mass boundary constraint: m(i) ≥ 5 mg.
• Where m(i) evaluates < 5 mg, mass is dynamically reallocated from the lowest-scoring CES node proportionally.
VI-B | Node Architecture Reference Table
Operational blue-printing guide mapping the six biological nodes. Use this structural reference to program physical raw materials into dosing machines.
| Node | Functional Role | DSV Dim. | Typical Mass Target | CES Min. | Tier Min. | Key Architecture Logic |
|---|---|---|---|---|---|---|
| Node 1 | Primary Driver | D1 Genomic | 250 – 300 mg | 6.5 | T2 | Acts as the anchor therapeutic driver; targets primary transcriptional/epigenetic loops. |
| Node 2 | Secondary Driver | D2 Metabolic | 150 – 200 mg | 5.5 | T2 | Targets metabolic flux workarounds; synergizes with mitochondrial pathway regulations. |
| Node 3 | Synergy Node A | D3 Redox | 80 – 120 mg | 4.5 | T3 | Provides active redox regulation; protects cellular matrices from radical buildup. |
| Node 4 | Synergy Node B | D4 Immune | 80 – 120 mg | 4.5 | T3 | Modulates local cytokine microenvironments; supports macroimmune system actions. |
| Node 5 | Epigenetic Regulator | D5 Epigenetic | 50 – 100 mg | 4.0 | T4 | Secures histone/acetylation status; stabilizes transcriptional gene access profiles. |
| Node 6 | Kinetic Adjuvant | D6 ADME | 10 – 50 mg | 5.0 | T2 | Limits enzymatic breakdown pathways (CYP/P-gp); extends active life of other nodes. |